目的 探討心腦康膠囊聯(lián)合曲美他嗪治療冠心病心絞痛的臨床療效。方法 選取2015年7月-2016年7月在天津市武清區(qū)中醫(yī)醫(yī)院治療的冠心病心絞痛患者82例，根據(jù)治療方案的差別分為對(duì)照組（41例）和治療組（41例）。對(duì)照組口服鹽酸曲美他嗪片，1片/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服心腦康膠囊，4粒/次，3次/d。兩組患者均治療8周。治療后，觀察兩組患者的臨床療效，并比較兩組的臨床癥狀、血清細(xì)胞因子、血液流變學(xué)指標(biāo)的變化。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為82.93%、97.56%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者心絞痛發(fā)作次數(shù)、心絞痛持續(xù)時(shí)間和硝酸甘油用量均少于同組治療前（P<0.05），且治療組減少的更顯著（P<0.05）。兩組患者血清CRP、IL-6、sICAM-1、sVCAM-1、cTnI和NT-proBNP水平均顯著降低，VEGF和NO水平顯著升高（P<0.05）；且治療組上述指標(biāo)改善的更明顯（P<0.05）。兩組WBV、PV和FIB均低于同組治療前（P<0.05），且治療組降低的更顯著，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 心腦康膠囊聯(lián)合曲美他嗪治療冠心病心絞痛效果顯著，可明顯改善患者癥狀及血清學(xué)指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical curative effect of Xinnaokang Capsules combined with trimetazidine in treatment of coronary heart disease with angina pectoris. Methods Patients (82 cases) with coronary heart disease with angina pectoris in Wuqing Hospital of Traditional Chinese Medicine in Tianjin from July 2015 to July 2016 were divided into control group (41 cases) and treatment group (41 cases) based on different treatments. Patients in control group were po administered with Trimetazidine Dihydrochloride Tablets, 1 tablet/time, three times daily. Patients in treatment group were po administered with Xinnaokang Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and clinical symptoms, serum cytokines, and blood rheology indexes were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.93% and 97.56%, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris, and dosage of nitroglycerin were lower than those before treatment (P<0.05). And those indexes in the treatment group were decreased more significantly than those in the control group (P<0.05). CRP, IL-6, sICAM-1, sVCAM-1, cTnI, and NT-proBNP in two groups were decreased significantly, but VEGF and NO increased significantly (P<0.05). And those indexes in the treatment group were improved more significantly than those in the control group (P<0.05). WBV, PV, and FIB in two groups were lower than those in the control group (P<0.05). And those indexes in the treatment group were decreased more significantly than those in the control group, and there were differences between two groups (P<0.05). Conclusion Xinnaokang Capsules combined with trimetazidine has a significant clinical effect in treatment of coronary heart disease with angina pectoris, and can significantly improve the symptoms and blood rheology indexes, which has a certain clinical application value.